Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 8/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539960 | 0.96 | MGLL (0.59) | CYP4F2CYP4A11MGLLBCHEFFAR1 | |
| SCHEMBL5543343 | 0.94 | MGLL (0.61) | CYP4F2CYP4A11MGLLBCHEFFAR1 | |
| SCHEMBL5542749 | 0.94 | MGLL (0.61) | CYP4F2CYP4A11MGLLBCHEFFAR1 | |
| SCHEMBL5536013 | 0.91 | CYP4F2 (0.60) | CYP4F2CYP4A11MGLLBCHEFFAR1 | |
| SCHEMBL5544329 | 0.87 | MGLL (0.49) | MGLLFFAR1MAOBMAOA | |
| SCHEMBL5542389 | 0.85 | LTA4H (0.60) | MGLLBCHEFFAR1 | |
| SCHEMBL5545614 | 0.84 | FFAR1 (0.50) | CYP4F2CYP4A11MGLLBCHEFFAR1 | |
| SCHEMBL5538042 | 0.83 | BCHE (0.57) | CYP4F2CYP4A11MGLLBCHEFFAR1 | |
| SCHEMBL5543700 | 0.81 | LTA4H (0.59) | MGLLBCHEFFAR1 | |
| SCHEMBL19405842 | 0.81 | CYP4F2 (0.62) | CYP4F2CYP4A11MGLLBCHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP4F2 954/4885CYP4A11 1804/4885MGLL 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.